Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept

키워드

참고문헌 (82)

1. Lallana EC, "Toxicities of immunosuppressive treatment of autoimmune neurologic diseases", Curr Neuropharmacol, 9, pp.468~477 (2011)
2. Rosman Z, "Biologic therapy for autoimmune diseases : an update", BMC Med, 11, pp.88~ (2013)
3. Li P, "Drugs for autoimmune inflammatory diseases : from small molecule compounds to anti-TNF biologics", Front Pharmacol, 8, pp.460~ (2017)
4. Lee DS, "B cell depletion therapies in autoimmune disease : advances and mechanistic insights", Nat Rev Drug Discov, 20, pp.179~199 (2021)
5. Tony HP, "Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases : experience from a national registry(GRAID)", Arthritis Res Ther, 13, pp.R75~ (2011)
6. Jayaraman J, "CAR-T design : elements and their synergistic function", EBioMedicine, 58, pp.102931~ (2020)
7. Goodnow CC, "The need for central and peripheral tolerance in the B cell repertoire", Science, 248, pp.1373~1379 (1990)
8. Nemazee D, "Mechanisms of central tolerance for B cells", Nat Rev Immunol, 17, pp.281~294 (2017)
9. Bhoj VG, "Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy", Blood, 128, pp.360~370 (2016)
10. Majzner RG, "Tumor antigen escape from CAR T-cell therapy", Cancer Discov, 8, pp.1219~1226 (2018)
11. Poole BD, "Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus", Arthritis Rheum, 60, pp.848~859 (2009)
12. Tebbe B, "Epidemiology and socioeconomic impact of skin disease in lupus erythematosus", Lupus, 6, pp.96~104 (1997)
13. Yaniv G, "A volcanic explosion of autoantibodies in systemic lupus erythematosus : a diversity of 180 different antibodies found in SLE patients", Autoimmun Rev, 14, pp.75~79 (2015)
14. Bruce IN, "Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus", J Comp EffRes, 11, pp.765~777 (2022)
15. Murphy G, "Effect of gender on clinical presentation in systemic lupus erythematosus", Rheumatology(Oxford), 52, pp.2108~2115 (2013)
16. Shlomchik MJ, "The role of B cells in lpr", lpr-induced autoimmunity, 1994, pp.180, 1295~1306
17. Jacob N, "B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice", J Immunol, 186, pp.4984~4993 (2011)
18. Bekar KW, "Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus", Arthritis Rheum, 62, pp.2443~2457 (2010)
19. Reddy V, "B-cell depletion in SLE : clinical and trial experience with rituximab and ocrelizumab and implications for study design", Arthritis Res Ther, 15(Suppl 1), pp.S2~ (2013)
20. Kansal R, "Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus", Sci Transl Med, 11, pp.eaav1648~ (2019)
21. Jin X, "Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus", Cell Mol Immunol, 18, pp.1896~1903 (2021)
22. Mougiakakos D, "CD19-targeted CAR T cells in refractory systemic lupus erythematosus", N Engl J Med, 385, pp.567~569 (2021)
23. Schett G, "OP0279 CAR-T cell treatment of refractory systemic lupus erythematosus-safety and preliminary efficacy data from the first four patients", Ann Rheum Dis, 81, pp.185~ (2022)
24. Zhang W, "Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR", Stem Cell Rev Rep, 17, pp.2120~2123 (2021)
25. Amagai M, "Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion", Cell, 67, pp.869~877 (1991)
26. Shimizu A, "Ultrastructural changes in mice actively producing antibodies to desmoglein 3 parallel those in patients with pemphigus vulgaris", Arch Dermatol Res, 294, pp.318~323 (2002)
27. Kasperkiewicz M, "Pemphigus", Nat Rev Dis Primers, 3, pp.17026~ (2017)
28. Sanders SL, "Pemphigus and pemphigoid", Med Clin North Am, 49, pp.681~694 (1965)
29. Joly P, "First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus(Ritux 3) : a prospective, multicentre, parallel-group, open-label randomised trial", Lancet, 389, pp.2031~2040 (2017)
30. Werth VP, "Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris", N Engl J Med, 384, pp.2295~2305 (2021)
31. Eming R, "Rituximab exerts a dual effect in pemphigus vulgaris", J Invest Dermatol, 128, pp.2850~2858 (2008)
32. Lunardon L, "Adjuvant rituximab therapy of pemphigus : a single-center experience with 31 patients", Arch Dermatol, 148, pp.1031~1036 (2012)
33. Ellebrecht CT, "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease", Science, 353, pp.179~184 (2016)
34. Lee J, "Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris", J Clin Invest, 130, pp.6317~6324 (2020)
35. Chang DJ, "A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris(mPV)patients : early cohort clinical and translational data", J Invest Dermatol, 142, pp.S1~ (2022)
36. Mueller KT, "Cellular kinetics of CTL019 in relapsed", refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, 2017, pp.130, 2317~2325
37. Cornec D, "B cells in Sjögren’s syndrome : from pathophysiology to diagnosis and treatment", J Autoimmun, 39, pp.161~167 (2012)
38. Julie Mielle, "B cells in Sjögren’s syndrome: from pathophysiology to therapeutic target", Rheumatology, 60(6), pp.2545~2560 (2019), Oxford University Press (OUP)[DOI]
39. Devauchelle-Pensec V, "Treatment of primary Sjögren syndrome with rituximab : a randomized trial", Ann Intern Med, 160, pp.233~242 (2014)
40. Brown S, "The TRACTISS protocol : a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren’s Syndrome", BMC Musculoskelet Disord, 15, pp.21~ (2014)
41. Chowdhury F, "Biological therapy in primary Sjögren’s syndrome: effect on salivary gland function and inflammation", Front Med(Lausanne), 8, pp.707104~ (2021)
42. Bowman SJ, "Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome", Arthritis Rheumatol, 69, pp.1440~1450 (2017)
43. Szyszko EA, "Salivary glands of primary Sjögren’s syndrome patients express factors vital for plasma cell survival", Arthritis Res Ther, 13, pp.R2~ (2011)
44. Meng H, "La", SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease, 2018, pp.192, 40~49
45. Fayyaz A, "Autoantibodies in Sjögren’s syndrome", Rheum Dis Clin North Am, 42, pp.419~434 (2016)
46. Lescoat A, "Therapeutic approaches to systemic sclerosis : recent approvals and future candidate therapies", Clin Rev Allergy Immunol (2021)[DOI]
47. Yoshizaki A, "Pathogenic roles of B lymphocytes in systemic sclerosis", Immunol Lett, 195, pp.76~82 (2018)
48. Jordan S, "Effects and safety of rituximab in systemic sclerosis : an analysis from the European Scleroderma Trial and Research(EUSTAR)group", Ann Rheum Dis, 74, pp.1188~1194 (2015)
49. Daoussis D, "A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease", Semin Arthritis Rheum, 46, pp.625~631 (2017)
50. Ebata S, "Safety and efficacy of rituximab in systemic sclerosis(DESIRES) : a doubleblind, investigator-initiated, randomised, placebo-controlled trial", Lancet Rheumatol, 3, pp.e489~e497 (2021)
51. Garvey B, "Rituximab in the treatment of autoimmune haematological disorders", Br J Haematol, 141, pp.149~169 (2008)
52. Rodrigo C, "Rituximab in the treatment of autoimmune haemolytic anaemia", Br J Clin Pharmacol, 79, pp.709~719 (2015)
53. Stone JH, "Rituximab versus cyclophosphamide for ANCA-associated vasculitis", N Engl J Med, 363, pp.221~232 (2010)
54. Jones RB, "Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis : 2-year results of a randomised trial", Ann Rheum Dis, 74, pp.1178~1182 (2015)
55. Waters P, "Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis", Arch Neurol, 65, pp.913~919 (2008)
56. Watanabe S, "Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica", Mult Scler, 13, pp.128~132 (2007)
57. Tahara M, "Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders(RIN-1 study) : a multicentre, randomised, double-blind, placebo-controlled trial", Lancet Neurol, 19, pp.298~306 (2020)
58. Cree BAC, "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder(N-MOmentum) : a double-blind, randomised placebo-controlled phase 2", 3 trial, 2019, pp.394, 1352~1363
59. Gilhus NE, "Myasthenia gravis", Nat Rev Dis Primers, 5, pp.30~ (2019)
60. Lazaridis K, "Myasthenia gravis : autoantibody specificities and their role in MG management", Front Neurol, 11, pp.596981~ (2020)
61. Behin A, "New pathways and therapeutic targets in autoimmune myasthenia gravis", J Neuromuscul Dis, 5, pp.265~277 (2018)
62. Litchman T, "Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients : a single-center retrospective study", J Neurol Sci, 411, pp.116690~ (2020)
63. Nowak RJ, "Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis : the BeatMG study", Neurology, 98, pp.e376~e389 (2021)
64. "Cartesian therapeutics to present late-breaking data from phase 1/2a trial of RNA CAR T-cell therapy in patients with generalized myasthenia gravis" (2022)[URL]
65. "Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART" (2022)[URL]
66. Oh SM, "Muscle-specific tyrosine kinase chimeric autoantibody receptor T cells(MuSK-CAART) : a precision cellular immunotherapy for antigen-specific B cell depletion in MuSK myasthenia gravis", Mol Ther, 30, pp.15~ (2022)
67. Marino M, "Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis", Front Immunol, 11, pp.613~ (2020)
68. Zografou C, "Short-and long-lived autoantibody-secreting cells in autoimmune neurological disorders", Front Immunol, 12, pp.686466~ (2021)
69. Stathopoulos P, "Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis", JCI Insight, 2, pp.e94263~ (2017)
70. Wolbert J, "Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies", JCI Insight, 5, pp.e132411~ (2020)
71. Bright RJ, "Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy : a systematic review", BMC Neurol, 14, pp.26~ (2014)
72. Hahn AF, "Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, shamcontrolled, cross-over study", Brain, 119, pp.1055~1066 (1996)
73. Roux T, "Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases", J Peripher Nerv Syst, 23, pp.235~240 (2018)
74. Querol L, "Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins", Neurol Neuroimmunol Neuroinflamm, 2, pp.e149~ (2015)
75. Stuhlmüller B, "Disease specific autoantibodies in idiopathic inflammatory myopathies", Front Neurol, 10, pp.438~ (2019)
76. Xiong A, "Rituximab in the treatment of immune-mediated necrotizing myopathy : a review of case reports and case series", Ther Adv Neurol Disorder, 14, pp.1756286421998918~ (2021)
77. Dai Z, "T cells expressing CD5", CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape, 2022, pp.7, 85~
78. Gomes-Silva D, "CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies", Blood, 130, pp.285~296 (2017)
79. Pan J, "Donor-derived CD7chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia : first-in-human, phase I trial", J Clin Oncol, 39, pp.3340~3351 (2021)
80. Schmidt D, "CD4+ CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity", J Clin Invest, 97, pp.2027~2037 (1996)
81. Moll M, "CD7-negative helper T cells accumulate in inflammatory skin lesions", J Invest Dermatol, 102, pp.328~332 (1994)
82. Bishu S, "Autoimmune enteropathy with a CD8+ CD7-T-cell small bowel intraepithelial lymphocytosis : case report and literature review", BMC Gastroenterol, 11, pp.131~ (2011)

관련 논문AI추천